1Kohno S,Koga H,Oka M. The pattern of respiratory infection in patients with lung cancer[J].{H}Tohoku Journal of Experimental medicine,1994,(04):405-411.
2Johnson BA,Long Q. Survival ensembles by the sum of pair-wise differences with application to lung cancer microarray studies[J].Ann Appl Stat,2011,(2A):1081-1101.
5Young R P, Hopkins R J, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history[J]. Eur Respir J, 2009, 34(2): 380-386.
6Rice T W, Blackstone E H, Ruseh V W. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction [J]. Ann Surg Oncol, 2010, 17(7) : 1721 - 1724.
7Benharroch D, Osyntsov L. Infectious diseases are analogous with cancer. Hypothesis and implications[ J]. J Cancer, 2012, 3 : 117 -121.
8Miceli M H, Diaz J A, Lee S A. Emerging opportunistic yeast in- fections[J]. Lancet Infect Dis, 2011, 11(2) : 142 -151.
9Gibbs BF, Schmutzler W, Vollrath IB, et al. Ambroxol inhibits the release of histamine,leukotrienes and cytokines from human leu- kocytes and mast cells[J]. Inflamm Res, 1999,48(2) : 86-93.
10Seifart C, Clostermann U, Seifart U, et al. Cell-specific modulation of surfactant proteins by ambroxol treatment [J]. Toxicol Appl Pharmacol,2005,203(1) : 27-35.
